Impact

Created in 2002 by the Fund’s Partners, a group of UK public sector research establishments led by STFC, BBSRC, NERC and Dstl, the Fund’s primary objective is to commercialise high quality science. We help establish technology companies that stem out of research by investing in the earliest and riskiest stages of businesses.

Since the Fund’s inception, it has made a significant contribution to the commercialisation objectives of its founding partners. The Fund is willing to take risks where there is a lot of uncertainty but also sufficient opportunity to create economic impact and/or public benefit, if successful.

Overall, the risks taken have resulted in a continuing economic value and impact along with wider benefits which can also be seen in some case studies.

Latest News

UK biotech to manufacture novel medicines for Inflammatory Bowel Disease...

26/03/2018 Three leading British biotechnology businesses have obtained grant funding from Innovate UK to...

read more

CellCentric’s first-in-class p300/CBP inhibitor drug CCS1477; capsule production complete ready...

Production of CCS1477 in capsule form is now complete, ahead of forthcoming first-in-human clinical...

read more